27, 296–303 (1998)
PM970266
PREVENTIVE MEDICINE
ARTICLE NO.
Transdermal Nicotine Replacement for Hospitalized Patients:
A Randomized Clinical Trial1
Stephen F. Lewis, M.D.,*, † Thomas M. Piasecki, M.S.,*, ‡ Michael C. Fiore, M.D., M.P.H.,*, † ,2
Jane E. Anderson, R.N., M.S.,* and Timothy B. Baker, Ph.D.*, ‡
*Center for Tobacco Research and Intervention and ‡ Department of Psychology, University of Wisconsin at Madison,
Madison, Wisconsin 53706; and †Department of Medicine, University of Wisconsin Medical School, Madison, Wisconsin 53706
Background. This study was undertaken to assess
the safety and efficacy of a treatment involving brief
counseling and the nicotine patch among hospital inpatients and to identify variables associated with longterm smoking cessation following hospitalization.
Methods. One hundred eighty-five patients were randomly assigned to one of three smoking cessation interventions: (1) A Minimal Care (MC) condition, consisting
of a brief physician-delivered motivational message to
stop smoking, (2) a Counseling 1 Active Nicotine Patch
(CAP) condition in which patients received the motivational message, a 6-week supply of nicotine patches,
and extended bedside and telephone counseling, and
(3) a Counseling 1 Placebo Patch (CPP) condition identical to the CAP condition except the supplied patches
contained no nicotine.
Results. At 6-month follow-up, abstinence rates for
the three treatments were 4.9, 6.5, and 9.7% for the MC,
CPP, and CAP treatments, respectively. These differences were not statistically significant. Patients admitted for respiratory disease were more likely to quit
than patients with any other diagnosis. The nicotine
patch was well tolerated by hospital inpatients.
Conclusions. The initiation of nicotine patch therapy
during hospitalization appears to be safe when used
among patients carrying a wide range of diagnoses .
Our study provided no evidence of the superiority of
nicotine patches versus placebo, but this does not preclude the possibility that future research using larger
samples might detect differences between patch
groups. Hospital interventions for smoking cessation
may be most effective among patients hospitalized for
a smoking-related illness such as respiratory disease. q1998 American Health Foundation and Academic Press
1
This research was supported by a research grant provided by the
Elan Pharmaceutical Research Corporation, Gainsville, Georgia, and
Athlone, Ireland.
2
To whom reprint requests should be addressed at the Center for
Tobacco Research and Intervention, 7275 Medical Sciences Center,
1300 University Avenue, Madison, WI 53706.
Key Words: smoking cessation; inpatients; counseling; nicotine; cutaneous administration; randomized
controlled trial.
INTRODUCTION
Cigarette smoking is the leading preventable cause
of morbidity and mortality in our society, accounting
for more than 400,000 premature deaths in the United
States each year [1]. Smokers are in routine contact
with the health care system, providing ample opportunity for health care providers to intervene [2]. Mounting
evidence suggests that the relatively brief smoking cessation interventions that can be accommodated within
the practical constraints of an outpatient encounter are
effective and produce long-term smoking cessation
rates of 5–10% [3–6]. While such interventions have
important public health implications [3,5], their absolute effectiveness is relatively small compared with
more intensive interventions [5,7,8].
In contrast to the outpatient setting, hospitalization
represents a comparatively underexplored point of contact between smokers and the health care system [9].
Hospitalization may represent an ideal opportunity for
the delivery of smoking cessation interventions for several reasons [9]. For instance, hospitalization may represent a “teachable moment” during which a smoker’s
vulnerability to disease is made apparent and the
health benefits associated with smoking cessation become particularly salient and attractive [10]. Moreover,
since January 1995, all hospitals in the United States
are smoke-free in accordance with the mandate of the
Joint Commission on the Accreditation of Healthcare
Organizations [11]. Thus, hospitalization represents a
period of enforced smoking abstinence that can lay the
foundation for a successful quit attempt [9]. Finally,
hospitalization represents a time when physicians and
other health care professionals have convenient access
to the smoker, as well as the time necessary to provide
more detailed and personalized cessation advice than is
296
0091-7435/98 $25.00
Copyright q 1998 by American Health Foundation and Academic Press
All rights of reproduction in any form reserved.
HOSPITALIZED SMOKERS
possible during routine outpatient encounters. Perhaps
for these reasons, studies of smoking cessation interventions delivered to inpatients have revealed longterm quit rates (20–25%) that begin to rival those produced by intensive outpatient treatment programs
[8,9,12–14].
Nicotine replacement therapy has been demonstrated to be a powerful aid to smoking cessation
[15,16], but its efficacy has not been well studied in
hospitalized patients [9]. In the sole clinical trial with
true random assignment to nicotine replacement reported to date, Campbell and colleagues [17] failed to
find a difference in long-term cessation rates between
groups treated with either nicotine or placebo chewing
gum in a sample of 212 smokers hospitalized for smoking-related diseases. The nicotine patch may be better
suited for inpatient interventions because, unlike nicotine gum, it has a simple dosing schedule, it does not
require chewing ability, and prior research suggests
that its relative efficacy (compared with placebo) does
not depend upon adjuvant behavioral support [8,15].
In this paper, we report the results of a hospital-wide,
randomized, double-blind, placebo-controlled study
comparing three treatments: nicotine patch plus brief
counseling, placebo patch plus brief counseling, and a
minimal care intervention. The primary objectives were
(1) to determine whether the nicotine patch plus counseling increased long-term (6-month), biochemically
confirmed abstinence rates over those produced by either placebo patch treatment or minimal care; (2) to
identify variables associated with long-term cessation
after inpatient smoking cessation intervention; and (3)
to assess the safety of the nicotine patch for inpatients.
METHODS
Patients
Patients were 185 individuals admitted to the University of Wisconsin Hospital and Clinics, a 500-bed
teaching hospital in Madison, Wisconsin, between April
1, 1993, and February 1, 1995, who expressed an interest in quitting smoking. Inclusion criteria were: (1) age
$18 years, (2) patient report of regular cigarette use
for at least 1 year immediately preceding admission,
(3) patient report of smoking 10 cigarettes or more in
a single day during the week prior to admission, (4)
expression of a personal commitment to quit smoking,
(5) a willingness to participate in the study and ability
to provide informed consent, (6) clearance from the patient’s attending physician, and (7) medical appropriateness for nicotine patch treatment according to the
ProStep nicotine patch package insert. Exclusion criteria were: (1) patient report of drug or alcohol abuse
within 6 months of admission, (2) history of major psychiatric illness, (3) pregnant women or women of
childbearing age not using an acceptable method of
297
birth control, (4) use of nicotine-containing products
other than cigarettes (e.g., smokeless tobacco, pipes,
cigars, or nicotine gum), (5) generalized skin disorders
or known skin sensitivities, (6) terminal illness, (7) discharge planned within 24 h of admission, (8) admission
to intensive care unit, and (9) admission for unstable
angina, acute myocardial infarction, unstable arrhythmia, major cardiac or vascular surgery, or angioplasty.
The protocol was approved by the Institutional Review
Board of the University of Wisconsin Center for
Health Sciences.
Interventions
Patients were randomly assigned to one of three
interventions in this study. In the Minimal Care (MC)
condition, patients received only a brief (2–3 min)
motivational message to quit smoking and were provided with a copy of the National Cancer Institute’s
Clearing the Air self-help smoking cessation pamphlet
from the study physician (S.F.L.) on the day of randomization. In the Counseling 1 Active Nicotine Patch
(CAP) and the Counseling 1 Placebo Patch (CPP)
conditions the study physician answered questions
about smoking cessation, dispensed nicotine patches,
applied the first patch for the patient, and trained
patients to use the patches properly. As in the MC
condition, the physician provided a brief (2–3 min)
personalized motivational message encouraging the
patient to quit smoking. In all three treatment conditions, these physician-delivered motivational messages
were tailored to the individual, incorporating when
applicable patient’s health status and responses to
the Fagerstrom Tolerance Questionnaire.
The study nurse (J.E.A.) accompanied the study physician to the initial patient visits and provided brief
(10–15 min) phone counseling at 1, 3, 6, and 24 weeks
after the initiation of patch treatment. The phone counseling sessions incorporated basic techniques of cognitive-behavioral therapy and motivational interviewing.
While counseling sessions did not follow a standardized
script, a typical session can be described. In general, the
nurse would introduce herself and remind the patient
about the study. Patients were asked questions about
patch compliance and whether they had smoked since
the last contact with study staff. Patients who had discontinued patch use were encouraged to begin using
them again. The importance of total abstinence was
stressed to all patients, and its importance to both success in quitting and patch safety were emphasized. Any
success in quitting smoking was praised. When patients
had lapsed or were struggling with temptations to
smoke, the nurse pointed out whatever success they had
attained (e.g., quitting for several weeks or reducing
smoking rate sharply) and offered this as evidence of
the patient’s interest in cessation and ability to quit.
298
LEWIS ET AL.
The nurse also asked open-ended questions such as
“How are things going for you in general?” to communicate concern and to gain context to help generate potential coping strategies for the patient for use in preventing relapse. Finally, the nurse frequently reminded
patients of the Clearing the Air pamphlets they had
been given while hospitalized and encouraged them to
look over the pamphlet between sessions.
Procedure
As part of the admissions procedures, hospital staff
screened all incoming patients with two questions: (1)
“Do you smoke cigarettes?” and, if the patient said “yes,”
(2) “Are you interested in quitting smoking?” The names
and room assignments of all patients who responded
affirmatively to both questions were forwarded to the
research staff. As soon as possible after admission, the
study nurse reviewed the patient’s chart, interviewed
the patient in order to determine eligibility for the trial,
and obtained consent from both the patient and the
attending physician.
The patient was randomized to either the MC condition or a patch condition using a predetermined computer-generated randomization code. If the patient was
assigned to a patch intervention (CAP or CPP conditions), s/he was given two sets of patches (ProStep,
Lederle Laboratories) containing a total of 21 patches
each. One set was labeled “Patches for Weeks 1–3” and
comprised 21 22-mg patches (CAP condition) or identically appearing placebo patches (CPP condition). The
other set was labeled “Patches for Weeks 4–6” and comprised 21 11-mg patches (CAP condition) or identically
appearing placebo patches (CPP condition). Patches
were packaged and labeled with subject numbers, and
patch condition (active or placebo) was assigned according to a predetermined computer-generated randomization procedure. Both patients and study staff
were blinded with respect to patch dose.
Self-reported smoking status was determined for
patch condition patients during each phone counseling
session. Patients in all conditions were called 24 weeks
after their initial contact with the study physician for
assessment of self-reported smoking status. Patients in
any of the three conditions who reported not smoking
during the 7 days preceding the 24-week follow-up telephone call were asked to come to the hospital for biochemical corroboration of abstinence via expired breath
carbon monoxide.
Measures
At the initial nurse visit, all patients were administered a questionnaire that elicited information about
inclusion and exclusion criteria. The patient questionnaire included the Fagerstrom Tolerance Questionnaire
[18]. Patients also used 5-point Likert scales to rate
their confidence in their ability to stay smoke-free after
discharge, their motivation to quit smoking, the prevalence of smoking among their family and friends, and
their perceived degree of social support for smoking
cessation. Additional information regarding subject eligibility was obtained by chart reviews conducted by the
study physician. The reason for admission was also
obtained from patients’ charts. Each patient’s primary
reason for admission was classified using the major
categories of the International Classification of Diseases (ICD-9) [19] (e.g., patients with diagnostic codes
from 390 to 459 were categorized as “circulatory” and
diagnoses from 460 to 519 “respiratory”).
Data Analysis
The primary endpoint of the study was 6-month point
prevalence abstinence rate. Abstinence was defined as
a self-report of no cigarettes in the 7 days prior to the
6-month follow-up phone call, confirmed by a CO reading of 10 ppm or less. Abstinence rates were calculated
on an intent-to-treat basis; patients claiming abstinence but refusing to provide a breath sample were
considered smokers in the primary outcome analysis,
as were patients lost to follow-up. Three secondary outcome variables were available only for patients assigned to a patch condition (CAP and CPP groups).
These patients were queried about their smoking status
during phone counseling at 1, 3, and 6 weeks after
the initial intervention. Biochemical corroboration of
patient reports was not obtained at these time points.
Finally, CPP and CAP groups were compared on selfreported patch use compliance at 1-week follow-up.
The characteristics of the subjects assigned to the
three intervention conditions were compared using oneway ANOVAs for continuously distributed variables
and the x2 statistic for categorical variables. The three
conditions were compared on the primary outcome variable using the x2 statistic. For each intermediate followup point, we compared the proportion of CAP and CPP
patients who reported that they smoked no cigarettes
during the week prior to the phone contact, using the
x2 test. A series of univariate analyses was performed,
comparing abstinent and relapsed patients on baseline
variables, in order to identify variables related to longterm outcome. Additionally, we conducted a x2 analysis
limited to patch group patients only, testing whether
patch regimen compliance was related to 6-month outcome.
Patients assigned to the CAP and CPP conditions
were queried about adverse events during follow-up
phone calls with the study nurse at 1, 3, and 6 weeks
after initial intervention. These reports were tallied,
and the frequency of each type of adverse event in CAP
and CPP groups was compared using separate x2 tests
to assess the safety/tolerability of nicotine patch therapy for hospitalized patients.
HOSPITALIZED SMOKERS
TABLE 1
Comparison of Treatment Groups on Baseline Variables
MC
(n 5 61)
Measurea
Age
Cigarettes per day
Years smoked
FTQ
Confidenceb
Motivationb
Social supportb
Sex (female)
43.0
22.5
25.4
6.6
3.7
4.0
3.0
26
CPP
(n 5 62)
(11.6)
(10.6)
(12.7)
(1.9)
(1.1)
(0.9)
(1.0)
(42.6)
44.7
24.9
27.5
6.9
3.8
4.2
3.9
32
CAP
(n 5 62)
(13.6)
(10.9)
(13.8)
(1.7)
(1.1)
(0.9)
(1.3)
(51.6)
43.4
24.0
26.3
6.6
4.0
4.1
3.7
27
(13.6)
(15.8)
(13.4)
(2.1)
(1.2)
(0.9)
(1.1)
(44.3)
a
For all variables except sex, numbers represent means and standard deviations (in parentheses). For sex, number and percentage
(parentheses) are presented.
b
These variables were assessed using 5-point Likert scales. Higher
values indicate stronger endorsement of the attribute listed.
Note. MC, Minimal Care condition; CPP, Counseling 1 Placebo
Patch condition; CAP, Counseling 1 Active Patch condition; FTQ,
Fagerstrom Tolerance Questionnaire.
RESULTS
Table 1 summarizes baseline characteristics for the
three intervention groups. No statistically significant
differences among groups were observed. The typical
patient in the trial was in his/her mid-40s, was moderately nicotine dependent, smoked more than a pack per
day during the week prior to admission, had smoked
for over 25 years, reported “some” confidence in his/her
ability to quit smoking, reported “a lot” of motivation
to quit smoking, and reported his/her family and friends
to be “somewhat” to “very” supportive of a quit attempt.
Table 2 summarizes outcomes across treatment conditions. At 6-month follow-up, 7 (11.5%), 7 (11.3%), and
9 (14.5%) patients in the MC, CPP, and CAP groups,
respectively, self-reported abstinence over the 7 days
prior to the phone call. However, 4 patients in the MC
TABLE 2
One-Week Point-Prevalence Abstinence Rates by Treatment
Condition at Each Follow-Up Time Point
End point
1
3
6
6
a
week
weeksa
weeksa
months
MC
(n 5 61)
N (%)
—
—
—
3 (4.9)
CPP
(n 5 62)
N (%)
CAP
(n 5 62)
(N (%)
20
11
11
4
29
21
19
6
(32.3)
(17.7)
(17.7)
(6.5)
(46.7)
(33.8)
(30.6)
(9.7)
x2 (df)
2.73
4.21
2.81
1.11
(1)
(1)
(1)
(2)
P
0.10
0.04
0.09
0.57
a
Only CPP and CAP patients were queried about smoking status
at these end points. Biochemical confirmation of patient-reported
smoking status was not obtained at these time points.
Note. MC, Minimal Care condition; CPP, Counseling 1 Placebo
Patch condition; CAP, Counseling 1 Active Patch condition. P value
for 6-month analysis reflects the results of an omnibus, threegroup comparison.
299
group, 3 in the CPP group, and 3 in the CAP group
refused to provide CO samples. All remaining patients
claiming abstinence produced CO breath samples less
than 10 ppm. Thus, 6 (9.7%) patients in the CAP condition, 4 (6.5%) in the CPP condition, and 3 (4.9%) in the
MC condition were biochemically corroborated to be
abstinent at 6-month follow-up. Neither the self-reported nor the biochemically corroborated differences
were statistically significant. Point-prevalence self-reported abstinence rates were higher in the CAP condition than in the CPP condition at all intermediate follow-up points, but the difference only reached
statistical significance at 3 weeks postintervention. At
1-week follow-up, 34 (60%) of the CPP patients and 40
(70%) of the CAP patients reported having complied
with the patch regimen during the first week of treatment. This difference was not significant.
Abstinent and relapsed patients were compared on
all baseline variables listed in Table 1 to determine
whether these variables could forecast treatment outcome. None of these variables was significantly different between relapsed and abstinent patients. Patch
compliance was not related to outcome among patients
assigned to patch conditions.
Reason for admission was strongly related to followup status (x2(15) 5 41.39, P , 0.001). Patients admitted
for disease of the respiratory system had the highest
quit rate of all diagnostic groups; 6 (46%) of the 13
patients with respiratory diagnoses were CO-corroborated abstinent at 6-month follow-up. Quit rates were
much lower in other diagnostic groups. Four (13%) of
31 patients with musculoskeletal diagnoses, 1 (3%) of
29 injury/poisoning patients, 1 (5%) of 21 patients with
digestive system diagnoses, and 1 (25%) of 4 patients
given supplemental codes were abstinent at 6-month
follow-up. None of the 87 patients assigned to the remaining 11 disease categories was found abstinent at
long-term follow-up. In a series of post-hoc x2 comparisons, respiratory patients were the only group with a
quit rate higher than the combined rate of all other
classes (x2(1) 5 32.76, P , 0.00001). Of the 13 patients
in the respiratory diagnosis group, 7 were admitted for
asthma, 3 for pneumonia, 2 for bronchitis, and 1 for a
pneumothorax chest tube replacement.
Among those patients randomly assigned to wear a
patch (CAP and CPP groups), some 63 adverse experiences were reported in telephone contacts. For purposes
of analysis, nonunique adverse experiences (e.g., patch
site irritation that developed into erythema) were combined, resulting in a total of 59 unique adverse experiences in the two groups. Table 3 provides a summary
of these reports. Dermal reaction at the patch site was
by far the most common adverse experience reported.
No significant differences were found between groups
in the frequency of any adverse event, and the pattern
of adverse events was very similar to that reported by
300
LEWIS ET AL.
TABLE 3
Frequencies of Self-Reported Adverse Experiences in the Two
Patch Conditions
CPP (n 5 62)
N (%)
Adverse experience
Dermal reaction at patch site
Nausea
Anxiety
Depression
Dizziness/lightheadedness
Upper respiratory infection
Headache
Diarrhea
Abdominal pain
Dyspnea
Othera
Total
11
3
1
1
1
1
1
2
1
0
7
29
(18)
(5)
(2)
(2)
(2)
(2)
(2)
(3)
(2)
(0)
(1)
(46)
CAP (n 5 62)
N (%)
16
4
0
0
0
0
1
1
0
1
7
30
(26)
(6)
(0)
(0)
(0)
(0)
(2)
(2)
(0)
(2)
(11)
(48)
a
This category largely comprises complications of factors unrelated
to patch use (e.g., infection of incision).
Note. CPP, Counseling 1 Placebo Patch condition; CAP, Counseling
1 Active Patch condition.
patients in outpatient smoking cessation clinical trials
[20–22]. Thus, the patch appeared to be well tolerated
by hospital inpatients.
DISCUSSION
This research evaluated the safety and efficacy of a
smoking cessation treatment for hospitalized smokers.
The program involved brief face-to-face physician counseling and low-intensity nurse-delivered telephone
counseling supplemented by either active or placebo
nicotine patches. Because of the small sample sizes used
in this research, only very large differences could
achieve statistical significance [23]. In fact, while the
CAP group was found to have the highest cessation rate
at all time points, treatment groups differed significantly on outcome at only one point in the follow-up
period; at 3-weeks posttreatment, patients receiving
counseling plus the active nicotine patch self-reported
higher cessation rates than did subjects receiving counseling plus the placebo patch.
Despite the lack of significant differences in longterm follow-up results, we believe the results may encourage future research for several reasons. First, the
results identified a population of smokers (those with
diagnoses of respiratory illness) that may be especially
receptive to smoking cessation treatment. The targeting of these patients for treatment might result in
high cessation rates. Second, although overall cessation
rates were low, the use of the nicotine patch 1 counseling intervention approximately doubled the likelihood
that a hospitalized patient would stop smoking relative
to minimal care. These results are consistent with those
of another recent clinical trial involving counseling and
nicotine replacement [12]. This trial investigated an
intervention consisting of inpatient counseling with a
nurse manager and the use of a videotape, workbook,
relaxation audiotape, optional nicotine replacement
therapy, and nurse-initiated follow-up phone counseling. This intervention increased cessation rates about
50% in comparison with usual care at 12-month followup. If the results of these two investigations accurately
represent the impact of a brief cessation intervention at
other hospital sites across the country, such treatments
might yield considerable public health benefits. Approximately 6.5 million smokers are hospitalized each year
[9]; a doubling of cessation rates for these smokers
would meaningfully reduce the morbidity and mortality
produced by smoking in this country.
It is a truism that any clinical trial failing to produce
a significant result may be said to be underpowered,
and thus, it is not necessarily surprising or informative
to note that our trial lacked statistical power. What
may be deemed informative for future investigators are
the estimates of relative effect size (an improvement of
50%) and absolute cessation rates (ranging from 5 to
10%) found in our trial. Knowledge of these parameters—knowledge we lacked at the design phase of our
trial—permits future investigators to compute more realistic sample size estimates for similar studies. The
outcome data from our trial suggest that approximately
450 patients would need to be assigned to each cell of
a future trial for a powerful test of the interventions
used. While this sample size estimate may seem unusually large, samples of this size are often used to test the
efficacy of minimal clinical interventions in outpatient
settings [3,6,7].
The cessation rate for the total sample in this study
(7%) was surprisingly closer to that typically observed
for minimal smoking cessation interventions delivered
in primary care conditions [3–6,8] than those reported
in hospitalized samples [9,13,14,17,24,27] or outpatient
nicotine patch trials [15]. Two facets of the research
design may account for this observation. First, we used
low-intensity behavioral interventions in this trial,
whereas many interventions for hospitalized smokers
and outpatient patch trials have utilized relatively intense, multimodal behavioral programs [12,14,15,24–
27]. Prior research has shown that the intensity of behavioral support is an independent contributor to
smoking cessation success in nicotine patch clinical trials [15]. A more aggressive counseling program featuring more frequent follow-up sessions, more face-to-face
contact, and routine CO testing might have boosted
cessation rates in the CPP and CAP groups. Second,
because the nicotine patch is contraindicated for patients with serious cardiovascular disease (e.g., recent
myocardial infarction or unstable or worsening angina)
[8], we used strict exclusion criteria for patients with
cardiovascular conditions, and eliminated many such
HOSPITALIZED SMOKERS
patients from this trial. Inpatients with serious cardiovascular conditions tend to be among the most successful at quitting smoking [9,17,27] and are either included
in [17,27] or are the exclusive focus [14,25,26] of many
studies of hospitalized smokers. Thus, our decision to
not sample from this unique subpopulation may have
undercut our long-term cessation rates. Two recent trials [30,31] have demonstrated that many of these patients can be safely treated with a conservative nicotine
patch regimen, suggesting that future trials of the nicotine patch for hospitalized smokers could incorporate
patients with coronary artery disease.
While modest, these success rates (5–10% long-term,
biochemically corroborated abstinence) may reflect realistic cessation outcomes for smokers admitted to a
general hospital. In fact, as noted above, these rates
are consistent with typical practice-wide cessation rates
resulting from outpatient minimal clinical interventions and are consistent with the meta-analytic results
for brief interventions published in the AHCPR Smoking Cessation Clinical Guideline [8] Trials of minimal
outpatient interventions and hospital interventions differ chiefly with respect to intervention intensity. While
outpatient studies often test the impact of simple physician advice to quit smoking, inpatient trials have
tended to use multimodal programs (i.e., written materials, tapes, and pharmacotherapy), a variety of providers, and multiple, lengthy counseling sessions. Our results may be interpreted as suggesting that the
inpatient cessation programs studied to date have
proven successful more as a result of the intensity of
their interventions and less as a result of some unique
state of readiness to quit produced by hospitalization. In
other words, if hospitalization represents a “teachable
moment,” it is because it affords health care providers
extended access to smokers during which intensive
treatments can be delivered; inpatients and outpatients
respond similarly to very brief interventions.
Consistent with other trials, we found that patients
hospitalized for respiratory diagnoses were especially
likely to quit smoking [17,27], regardless of the treatment condition to which they were assigned. The 13
respiratory patients in this trial constituted approximately 7% of the total sample. Six members of this
group (46%) had quit smoking by 6 months. It may
be theoretically and clinically important to explore the
reasons why this diagnostic group was especially responsive to cessation intervention. For instance, these
smokers might have been more likely to attribute their
disease to smoking, they might have expected greater
health benefits from quitting, they might have experienced more aversive effects of smoking secondary to
their disease process, and so on. In contrast to other
studies [17,27], none of the patients in our sample hospitalized for a circulatory diagnosis was successful in
quitting smoking. However, as mentioned above, this
301
study used strict exclusion criteria for patients with
cardiovascular disease. Patients in the study with circulatory diagnoses largely suffered from peripheral vascular problems as opposed to more significant or lifethreatening cardiovascular disease, and these conditions may not have been sufficiently distressing to inspire serious attempts to quit smoking.
An important finding of our study was that the nicotine patch was well tolerated by the noncardiac inpatients that were the focus of this study. The adverse
events reported by CAP patients tended to be very mild
and were very similar to the adverse events reported
by CPP patients. No serious or life-threatening adverse
event (i.e., arrhythmias or myocardial infarction) were
reported in either patch group. Moreover, the adverse
events profiles of both groups were very similar to those
reported in outpatient clinical trials of the nicotine
patch [20–22]. Thus, nicotine patch therapy appears
to be appropriate and safe for medically screened and
motivated hospital inpatients. Our efficacy analyses
cannot be used to argue that the nicotine patch is a
powerful intervention for use with hospitalized smokers. However, our safety findings may encourage wider
use of the patch by attending physicians and consult
services with their noncardiac inpatients who request
it or otherwise appear to be good candidates for nicotine
replacement therapy.
One procedural limitation needs to be kept in mind
when interpreting our efficacy findings. Our physician
advice and nurse follow-up interventions were designed
to require no patient hospital visits after discharge and
were intentionally brief to model the sort of treatment
that might reasonably be expected to be delivered in
the hectic “real world” of hospital practice. For this
reason, we collected CO samples from patients at only
the 6-month follow-up, well after they had exited the
formal treatment phase of the study. Thus, one must
eye the self-reported point-prevalence abstinence rates
from intermediate follow-ups with caution. Because CO
corroboration was not obtained at the intermediate follow-ups, we cannot know how seriously this affects the
self-reported point-prevalence abstinence rates, but CO
data from the 6-month follow-up may be used to speculate about the extent of the problem. No patient who
reported abstinence at 6 months was found to have a
CO greater than 10 ppm, but approximately 40% of
those patch group participants who reported not smoking at 6 months declined to be tested. Assuming these
patients were all attempting to deceive the outcome
assessor, then 40% may serve as a loose estimate of the
rate of inflation intratreatment abstinence rates. Thus,
deception may, at least in part, explain the apparently
high rate of relapse observed between the 6-week and
the 6-month follow-ups in our trial. A related procedural limitation of the study was the fact that the nurse
who performed the counseling was also responsible for
302
LEWIS ET AL.
determining and recording patients’ smoking status.
Some patch patients who had slipped may have deceived the counselor during phone sessions to shorten
the call or avoid embarrassment. Thus, some patch patients who refused to provide breath samples may have
done so to avoid having their deception discovered.
However, the fact that an even greater proportion of MC
patients declined to provide breath samples suggests
counselor contact and monitoring per se may not have
skewed the results overmuch.
We conclude that the nicotine patch is safe for use
among a general hospital population, but that larger,
more inclusive studies will be necessary to establish
its clinical efficacy in such a population. Patients who
perceive a clear link between smoking behavior and
their illness may be most likely to profit from smoking
cessation interventions delivered in the hospital setting. In future research, relatively intensive behavioral
support may be necessary to demonstrate the superiority of the active patches relative to placebo and produce
quit rates comparable with those found in specialized
outpatient smoking cessation clinics.
ACKNOWLEDGMENTS
The authors thank the admissions staff at UWHC for their help
in identifying and recruiting patients for this trial.
REFERENCES
1. U.S. Department of Health and Human Services. Reducing the
health consequences of smoking: 25 years of progress. A report
of the Surgeon General. Atlanta: U.S. Department of Health
and Human Services, Public Health Service, Centers for Disease
Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1989, Washington DC.
[DHHS Publication No. (CDC) 89-8411]
2. Centers for Disease Control and Prevention. Physician and other
health care professional counseling of smokers to quit: United
States, 1991. MMWR 1993;42:854–7.
3. Russell MAH, Wilson C, Taylor C, Baker CD. Effect of general
practitioner’s advice against smoking. Br Med J 1979;2:231–5.
4. Kottke TE, Battista RN, DeFries GH, Brekke M. Attributes of
successful smoking cessation interventions in medical practice:
a meta-analysis of 39 controlled trials. JAMA 1988;259:2882–9.
5. Glynn TJ. Relative effectiveness of physician-initiated smoking
cessation interventions for smoking cessation. Cancer Bull
1988;40:359–64.
6. Ockene JK, Kristeller J, Pbert L, Hebert JR, Luippold R, Goldberg RJ, et al. The Physician-Delivered Smoking Intervention
Project: can short-term interventions produce long-term effects
for a general outpatient population? Health Psychol 1994;
13:278–81.
7. Fiore MC, Piasecki TM, Baker TB. Signal and noise in minimal
interventions for smoking cessation. Tobacco Control 1995;
4:114–6.
8. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG,
Gritz ER, et al. Smoking cessation. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service,
Agency for Health Care Policy and Research, 1996 Apr. [AHCPR
Publication No. 96-0692, Clinical Practice Guideline No. 18]
9. Orleans CT, Kristeller JL, Gritz ER. Helping hospitalized smokers quit: new directions for treatment and research. J Consult
Clin Psychol 1993;61:778–89.
10. Emmons K, Goldstein MG. Smokers who are hospitalized: a window of opportunity for cessation interventions. Prev Med
1992;21:262–9.
11. Joint Commission on the Accreditation of Healthcare Organizations. Hospital standards—1992. Chicago: Joint Commission on
Accreditation of Healthcare Organizations, 1991.
12. Taylor CB, Miller NH, Herman S, Smith PM, Sobel D, Fisher L, et
al. A nurse-managed smoking cessation program for hospitalized
smokers. Am J Public Health 1996;86:1557–60.
13. Stevens VJ, Glasgow RE, Hollis J, Lichtenstein E, Vogt TM. A
smoking cessation intervention for hospital patients. Med
Care 1993;31:65–72.
14. Ockene J, Kristeller JL, Goldberg R, Ockene I, Merriam P, Barrett
S, et al. Smoking cessation and the severity of disease: the Coronary Artery Smoking Intervention Study. Health Psychol
1992;11:119–26.
15. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness
of the nicotine patch for smoking cessation: a meta-analysis.
JAMA 1994;271:1940–7.
16. Tang JL, Law M, Wald N. How effective is nicotine replacement
therapy in helping people to stop smoking? Br Med J 1994;
308:21–6.
17. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation
in hospital patients given repeated advice plus nicotine or placebo
chewing gum. Respir Med 1991;85:155–7.
18. Fagerstrom KO. Measuring degree of physical dependence to
tobacco smoking with reference to individualization of treatment.
Addict Behav 1978;3:235–41.
19. U.S. Department of Health and Human Services. The international classification of diseases, 9th revision, clinical modification: ICD-9-CM. 4th ed. Washington: U.S. Govt. Printing Office, 1991.
20. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double
blind trial of repeated treatment with transdermal nicotine for
relapsed smokers. Br Med J 1995;311:363–6.
21. Transdermal Nicotine Study Group. Transdermal nicotine for
smoking cessation: six-month results from two multicenter controlled clinical trials. JAMA 1991;266:3133–8.
22. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker
TB. Two studies of the clinical effectiveness of the nicotine patch
with different counseling treatments. Chest 1994;105:524–33.
23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed.
New York: Wiley, 1981.
24. Orleans CT, Rotberg HL, Quade D, Lees P. A hospital quit-smoking consult service: clinical report and intervention guidelines.
Prev Med 1990;19:198–212.
25. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking
cessation after acute myocardial infarction: effects of a nursemanaged intervention. Ann Intern Med 1990;113:118–23.
26. Rigotti NA, McKool KM, Shiffman SA. Predictors of smoking
cessation after coronary artery bypass graft surgery: results of
a randomized trial with 5-year follow-up. Ann Intern Med
1994;120:287–93.
27. Glasgow RE, Stevens VJ, Vogt TM, Mullooly JP, Lichtenstein E.
Changes in smoking associated with hospitalization: quit rates,
predictive variables, and intervention implications. Am J Health
Promot 1991;6:24–9.
28. Stanislaw AE, Wewers ME. A smoking cessation intervention
with hospitalized surgical cancer patients: a pilot study. Cancer
Nurs 1994;17:81–6.
HOSPITALIZED SMOKERS
29. Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling
on smoking cessation among patients hospitalized with chronic
obstructive pulmonary disease: a randomized clinical trial. Int
J Addict 1991;16:107–19.
30. Working Group for the Study of Transdermal Nicotine in Patients
with Coronary Artery Disease. Nicotine replacement therapy for
303
patients with coronary artery disease. Arch Intern Med
1994;154:989–95.
31. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC,
Steele BG, et al. The safety of transdermal nicotine as an aid to
smoking cessation in patients with cardiac disease. N Engl J
Med 1996;335:1792–8.